MYLK

Across TCGA pan-cancer cohorts, MYLK RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of MYLK’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where MYLK RNA is repressed in tumor relative to normal tissue. In most cancer types MYLK is over-expressed in tumor, although a few such as BLCA and COAD show the opposite, repressed pattern.

BLCA, COAD, and LUSC are the cancer types where MYLK tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYLK RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	IV	−4.837	<.001	11	view →
COAD	Male	II,III,IV	−2.673	<.001	10	view →
LUSC	Male	II,III,IV	−1.280	<.001	9	view →
KICH	Female	All	−2.857	<.001	8	view →
KIRP	All	III,IV	−1.408	<.001	8	view →
LUAD	Female	III,IV	−1.300	<.001	8	view →
THCA	All	II,III,IV	−0.828	<.001	8	view →
UCEC	All	All	−4.645	<.001	6	view →
BRCA	Female	All	−2.061	<.001	6	view →
HNSC	All	III,IV	+1.297	<.001	6	view →
STAD	Female	All	−3.389	<.001	5	view →
READ	Female	All	−4.274	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

MYLK–BLCA

Open the BLCA breakdown →